Medicalgorithmics, a Polish-based global provider of software for cardiac diagnostics, has signed a service agreement for the implementation of a clinical study that addresses the detection of atrial fibrillation after non-cardiac surgery. The study will utilize the company’s proprietary AI algorithms and PocketECG devices. The agreement with the Population Health Research Institute (PHRI), a joint institute of Hamilton Health Sciences and McMaster University, is set for 24 months and will involve centers located in Canada and Spain, with the potential for expansion to additional countries.
The aim of the study led by PHRI is to detect atrial fibrillation after operations that were not directly related to the heart and circulatory system. As part of the agreement, PHRI will rent 60 PocketECG devices and utilize a platform for analyzing ECG results, using artificial intelligence algorithms to diagnose cardiac disorders. Medicalgorithmics will provide real-time ECG monitoring and notification of critical events for the duration of the study.
“Collaboration in clinical research execution is a new area of business development for Medicalgorithmics, which we are successfully expanding on a global scale. Particularly promising is the cardiovascular domain in new drug trials, but as you can see, we are also establishing collaborations in other trials with success. Medicalgorithmics is one of the few global suppliers with first-class technology capable of supporting clinical trial implementation in this way. This is largely due to our presence in many international markets,” says Magdalena Ślusarczyk, Director of Clinical Affairs and Product Implementation at Medicalgorithmics.
According to the company’s development strategy for 2023-26, commercial participation in clinical trials is to be one of Medicalgorithmics’ new business legs. The signing of the new agreement means that the Polish med-tech is now involved in three such projects. The two earlier ones are a collaboration with Simbec Orion, which saw the actual testing phase of a new drug, an oral CHIT1 inhibitor (OATD-01) in around 100 patients with active pulmonary sarcoidosis, start in Q1. The company is also providing cardiac safety services in the GOAL-HF clinical trial being conducted by Swedish biopharmaceutical company AnaCardio.
Both projects use PocketECG heart monitoring devices together with a diagnostic platform. Supported by artificial intelligence algorithms, the system enables real-time remote monitoring of the heart rate of patients taking part in trials of new substances.
Medicalgorithmics is actively discussing participation in further international clinical trial projects as a cardiac monitoring provider.